Olema Pharmaceuticals, INC Form 4 insider transactions

Graham Walmsley, a director of Olema Pharmaceuticals, amends a previous SEC filing to include the indirect beneficial ownership of 1,800,000 shares held by Logos Global Master Fund LP.

David C. Myles, Chief Discovery & Non-Clinical Development Officer at Olema Pharmaceuticals, was granted stock options to purchase 205,000 shares of common stock.

Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals, received stock options for 205,000 shares on February 28, 2025, according to a Form 4 filing.

Shawnte Mitchell, Chief Legal Officer of Olema Pharmaceuticals, was granted stock options to purchase 450,000 shares of common stock.

Shane William Charles Kovacs, Chief Operating and Financial Officer of Olema Pharmaceuticals, was granted stock options to purchase 320,000 shares of common stock.

Olema Pharmaceuticals' CEO, Sean Bohen, was granted stock options for 650,000 shares on February 28, 2025, as reported in a Form 4 filing with the SEC.

BVF Partners and related entities exchanged 420,000 shares of Olema Pharmaceuticals common stock for an equal number of pre-funded warrants.

Bain Capital Life Sciences Opportunities IV, L.P. exchanged 3,500,000 shares of Olema Pharmaceuticals common stock for a pre-funded warrant to purchase the same number of shares, while also purchasing 300,000 shares at an average price of $5.7579.

A director of Olema Pharmaceuticals, Graham G. Walmsley, filed an amended SEC Form 4 to correct errors in a previous filing regarding a share transaction between two investment funds under his control.

Graham G. Walmsley, a director at Olema Pharmaceuticals, executed an intra-fund transfer of 700,761 common shares between two Logos funds he manages.

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, exercised stock options for 14,000 shares at $4.87 per share on December 16, 2024.

An Olema Pharmaceuticals executive sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

An Olema Pharmaceuticals executive sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

Olema Pharmaceuticals' Chief Medical Officer sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

Olema Pharmaceuticals' Chief Operating and Financial Officer, Shane Kovacs, sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

Olema Pharmaceuticals CEO, Sean Bohen, sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

BVF Partners and related entities exchanged 3,420,000 shares of Olema Pharmaceuticals common stock for an equal number of pre-funded warrants and also acquired additional pre-funded warrants in a private placement.

A director of Olema Pharmaceuticals, Graham Walmsley, has amended a previous SEC filing to correct the date of a stock transaction.

Shane Kovacs, Chief Operating and Financial Officer of Olema Pharmaceuticals, exercised stock options and acquired shares, increasing his total holdings in the company.

Paradigm Biocapital Advisors LP reports a decrease in its ownership of Olema Pharmaceuticals common stock following recent transactions.

Director Cyrus Harmon of Olema Pharmaceuticals sold shares of common stock on July 29 and July 30, 2024, under a pre-arranged 10b5-1 trading plan.

Director Cyrus Harmon of Olema Pharmaceuticals sold 5,000 shares of common stock at an average price of $12.26, according to a Form 4 filing with the SEC.

Director Cyrus Harmon of Olema Pharmaceuticals sold 20,000 shares of common stock on June 28, 2024, at a weighted average price of $10.77, pursuant to a pre-arranged 10b5-1 trading plan.

BVF Partners and affiliated entities report changes in beneficial ownership of Olema Pharmaceuticals, including the acquisition of stock options and adjustments to direct and indirect holdings.

Director Sandra Horning acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.

Director G. Walmsley Graham acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.

Director Cyrus Harmon acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.

Director Andrew Rappaport acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.

Yi Larson, a director of Olema Pharmaceuticals, acquired 23,000 stock options on June 14, 2024, at an exercise price of $12.36.

Director Gorjan Hrustanovic acquired 23,000 stock options in Olema Pharmaceuticals, according to a recent SEC filing.